Welcome to our dedicated page for Capricor Therapeutics news (Ticker: CAPR), a resource for investors and traders seeking the latest updates and insights on Capricor Therapeutics stock.
Capricor Therapeutics Inc (NASDAQ: CAPR) generates news primarily around its development of cell and exosome-based therapeutics for rare diseases, with a strong focus on Duchenne muscular dystrophy (DMD). The company’s announcements frequently highlight clinical trial milestones for its lead investigational therapy, Deramiocel (CAP-1002), as well as updates on its StealthX™ exosome platform.
Investors and followers of CAPR news can expect detailed coverage of clinical trial results and regulatory interactions. Recent communications include positive topline results from the pivotal Phase 3 HOPE-3 study of Deramiocel in DMD, information on primary and secondary endpoints such as Performance of Upper Limb (PUL v2.0) and left ventricular ejection fraction, and commentary from clinical investigators. Capricor also reports on its engagement with the U.S. Food and Drug Administration, including a Complete Response Letter for its Biologics License Application and subsequent Type A meeting to align on the role of HOPE-3 data in the regulatory pathway.
News items also cover corporate and financial developments, such as quarterly financial results, public offerings of common stock, and manufacturing readiness at the company’s GMP facility in San Diego, California. In addition, Capricor issues updates on scientific publications and conference presentations, including peer-reviewed work describing Deramiocel’s mechanism of action and data on scalable loading of therapeutic oligonucleotides into exosomes.
For those tracking CAPR, this news feed provides a centralized view of clinical, regulatory, scientific and financing updates directly related to Capricor’s programs. Regular review of these items can help readers follow the progress of Deramiocel in DMD, developments in the StealthX™ platform, and key corporate decisions that shape the company’s therapeutic pipeline.
Capricor Therapeutics (NASDAQ: CAPR) announced positive results from the Phase II HOPE-2 study of CAP-1002 for DMD, showing significant improvements in upper limb performance (p=0.05) and cardiac function (p=0.004). The FDA has approved an expanded access program to treat additional COVID-19 patients, with the compassionate use cases reporting 100% survival. The company reported a net loss of $2.1 million for Q1 2020 but raised $12.8 million through offerings. Capricor plans to discuss the DMD approval pathway with the FDA and is expanding its vaccine platform against COVID-19.
Capricor Therapeutics (NASDAQ: CAPR) will release its Q1 2020 financial results after market close on May 14, 2020. A conference call and webcast for discussion will be held at 4:30 p.m. ET the same day. The company specializes in developing first-in-class biological therapeutics, notably its lead candidate CAP-1002, an allogeneic cell therapy aimed at treating Duchenne muscular dystrophy. Further details about its products and business strategy will be communicated during the event.
Summary not available.